Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07668557 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Anti-CD33-CLL1 CAR-T Cells (ICG415) for the Treatment of Relapsed/Refractory Acute Myeloid Leukemia

Study acronym: ICG415-AML-01
StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
This single-arm, open-label phase I trial evaluates the safety and tolerability of ICG415, autologous CAR-T cells targeting CD33 and CLL1, in patients with relapsed or refractory acute myeloid leukemia (AML). Subjects receive lymphodepleting chemotherapy followed by autologous CAR-T infusion. The primary goal is to assess safety and preliminary anti-leukemic efficacy in patients failing standard AML therapies.
Trial Details
NCT Number NCT07668557
Lead Sponsor iCell Gene Therapeutics
Conditions
(from sponsor)		 Acute Myeloid Leukemia (AML)
Related terms Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute, Recurrence
Enrollment 18 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov